Last reviewed 2026-04-20 · How we verify

Teprin (CLOBENZTROPINE)

Phase 2 active Small molecule

Teprin (generic name: CLOBENZTROPINE) is a clobenztropine drug. It is currently in Phase 2 development.

Teprin is believed to work by modulating certain neurotransmitter systems in the brain.

Teprin, also known as clobenztropine, is a small molecule drug of the clobenztropine class. Its exact target and mechanism of action are unknown, but it is believed to work by modulating certain neurotransmitter systems in the brain. Teprin is not FDA-approved for any indications, and its commercial status, including patent status and generic availability, is also unknown. As a result, there is limited information available on its safety profile, pharmacokinetics, and clinical use. Further research is needed to fully understand the properties and potential applications of Teprin.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CLOBENZTROPINE
Drug class	clobenztropine
Target	Sodium-dependent dopamine transporter
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Think of neurotransmitters like messengers that help different parts of the brain talk to each other. Teprin is thought to help regulate the activity of these messengers, which can help to balance brain chemistry and alleviate symptoms of certain conditions. By doing so, Teprin may help to improve mood, reduce anxiety, or enhance cognitive function.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Teprin CI brief — competitive landscape report
Teprin updates RSS · CI watch RSS

Frequently asked questions about Teprin

What is Teprin?

Teprin (CLOBENZTROPINE) is a clobenztropine drug.

How does Teprin work?

Teprin is believed to work by modulating certain neurotransmitter systems in the brain.

What is the generic name of Teprin?

CLOBENZTROPINE is the generic (nonproprietary) name of Teprin.

What drug class is Teprin in?

Teprin belongs to the clobenztropine class. See all clobenztropine drugs at /class/clobenztropine.

What development phase is Teprin in?

Teprin is in Phase 2.

What does Teprin target?

Teprin targets Sodium-dependent dopamine transporter and is a clobenztropine.

Drug class: All clobenztropine drugs
Target: All drugs targeting Sodium-dependent dopamine transporter
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing